hit counter
Agios Pharmaceuticals, Inc. (AGIO) Stock News Sentiment & Price - Sentifly
AGIO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Agios Pharmaceuticals, Inc. (AGIO)

USA
Biotechnology
NASDAQ
AGIO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AGIO Latest news
Zacks Investment Research
Positive
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
2021-11-03 14:33

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.

Seeking Alpha
Neutral
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript
2021-11-03 12:45

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates
2021-11-03 09:58

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
2021-11-03 07:11

– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 –

Zacks Investment Research
Negative
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
2021-10-27 16:11

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
2021-10-21 16:01

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.

Seeking Alpha
Positive
Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced
2021-09-07 09:36

Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their own capital, put at risk in order to fill multi-million-$ trade orders placed by institutions managing multi-Billion-$ portfolios.

GlobeNewsWire
Neutral
Agios To Present at September Investor Conferences
2021-08-30 07:00

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:

InvestorPlace
Positive
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
2021-08-25 12:08

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

Zacks Investment Research
Positive
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
2021-08-18 11:29

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

Loading more news...